Imara to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Imara Inc. (Nasdaq: IMRA) is set to participate in two virtual investor conferences in September 2021. The company will take part in the SVB Leerink CybeRx Series on September 22 and 23, focusing on neuromuscular and rare diseases. Additionally, Rahul Ballal, Ph.D., President and CEO, will present at the 2021 Cantor Virtual Global Healthcare Conference on September 29 at 2:00 p.m. ET. A live webcast of the presentation will be available on the company’s website.

Imara is advancing IMR-687, a potential treatment for sickle cell disease and beta-thalassemia.

SVB Leerink CybeRx Series and 2021 Cantor Virtual Global Healthcare Conference

BOSTON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, today announced that the Company will be present at the following upcoming virtual investor conferences in September:

Imara will participate in the SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines 1x1 Event on September 22 and September 23, 2021.

Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara, will give a presentation at the 2021 Cantor Virtual Global Healthcare Conference on Wednesday, September 29, 2021 at 2:00 p.m. ET.   A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the company's website at www.imaratx.com.

About Imara
Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia. IMR-687 is being designed to have a multimodal mechanism of action that acts on red blood cells, white blood cells, adhesion mediators and other cell types. For more information, please visit www.imaratx.com.

Media Contact:
Marin Bergman
Ten Bridge Communications
818-516-2746
marin@tenbridgecommunications.com

Investor Contact:
Michael Gray
617-835-4061
mgray@imaratx.com

FAQ

What virtual investor conferences will Imara Inc. participate in September 2021?

Imara Inc. will participate in the SVB Leerink CybeRx Series on September 22-23, and the 2021 Cantor Virtual Global Healthcare Conference on September 29, 2021.

Who will present at the 2021 Cantor Virtual Global Healthcare Conference for Imara?

Rahul Ballal, Ph.D., President and CEO of Imara, will present at the conference on September 29, 2021.

When is Imara's presentation at the Cantor Virtual Global Healthcare Conference?

Imara's presentation at the Cantor Virtual Global Healthcare Conference is scheduled for September 29, 2021, at 2:00 p.m. ET.

What is the main focus of Imara's development efforts?

Imara is focused on developing novel therapeutics for rare inherited genetic disorders of hemoglobin, including sickle cell disease and beta-thalassemia.

What is IMR-687 being developed for?

IMR-687 is being developed as a potential disease-modifying treatment for sickle cell disease and beta-thalassemia.